Log in

NIKA NIKA PHARMACEUTICALS, INC OTC · United States

NIKA PHARMACEUTICALS, INC (NIKA) news

NIKA PHARMACEUTICALS, INC is a public biotech or pharmaceutical company listed on OTC under the ticker NIKA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest NIKA PHARMACEUTICALS, INC news

We have not published a story on NIKA PHARMACEUTICALS, INC yet. When there is news, it will appear here.

NIKA PHARMACEUTICALS, INC annual financials

LineFY2025FY2024
Revenue$0
Net income (loss)-$76,398-$95,792
Cash from operations-$79,654-$154,932
Cash and equivalents$1,889$2,083

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $2,932.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about NIKA PHARMACEUTICALS, INC

What is the ticker symbol of NIKA PHARMACEUTICALS, INC?

NIKA PHARMACEUTICALS, INC trades under the ticker NIKA on OTC.

Where is NIKA PHARMACEUTICALS, INC listed?

NIKA PHARMACEUTICALS, INC is listed on OTC.

Which country or territory is NIKA PHARMACEUTICALS, INC listed under?

Our directory records NIKA PHARMACEUTICALS, INC under United States.

Does aibio.space cover NIKA PHARMACEUTICALS, INC?

aibio.space lists NIKA PHARMACEUTICALS, INC among 2,820 public biotech companies and publishes its news here as stories appear.

Is NIKA PHARMACEUTICALS, INC profitable?

NIKA PHARMACEUTICALS, INC reported a net loss of $76,398 for the fiscal year ended Dec 31, 2025, and used $79,654 of cash in operations, per its annual report to the SEC.

How much cash does NIKA PHARMACEUTICALS, INC have?

$2,932 in cash at Jun 30, 2026, per its 10-Q.

Investor discussion: NIKA PHARMACEUTICALS, INC

Members talk about NIKA PHARMACEUTICALS, INC (NIKA). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open OTC:NIKA on TradingView.

Listing details

NIKA PHARMACEUTICALS, INC is a public biotech or pharmaceutical company listed on OTC under the ticker NIKA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
NIKA PHARMACEUTICALS, INC
Ticker
NIKA
Listing
OTC
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.